CytoDyn Inc…announced today updated results from its current cancer study using leronlimab (in varying doses) to treat 28 patients with CCR5+ Metastatic Triple-Negative Breast Cancer...75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004), as compared to a 980% increase in OS...The updated analysis also suggested a 580% increase in 12-month Progression Free Survival (“PFS”) (p = 0.0354), as compared to up to a 660% increase in PFS...